CG
TVTX icon

Cutler Group’s Travere Therapeutics TVTX Stock Holding History

Cutler Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$10K Sell
1,400
-600
-30% -$5.06K ﹤0.01% 1290
2023
Q4 		$17K Sell
2,000
-700
-26% -$5.1K ﹤0.01% 2078
2023
Q3 		$24K Buy
2,700
+700
+35% +$9.88K ﹤0.01% 1912
2023
Q2 		$30K Hold
2,000
– – ﹤0.01% 1609
2023
Q1 		$44K Hold
2,000
– – ﹤0.01% 1435
2022
Q4 		$42K Hold
2,000
– – ﹤0.01% 1696
2022
Q3 		$49K Hold
2,000
– – ﹤0.01% 1911
2022
Q2 		$48K Buy
+2,000
New +$50.3K ﹤0.01% 1977
2020
Q4 		– Sell
-800
Closed -$14K – 5501
2020
Q3 		$14K Sell
800
-800
-50% -$15.5K ﹤0.01% 2753
2020
Q2 		$32K Sell
1,600
-4,100
-72% -$65.3K ﹤0.01% 2061
2020
Q1 		$83K Sell
5,700
-200
-3% -$3.01K ﹤0.01% 1431
2019
Q4 		$83K Sell
5,900
-200
-3% -$2.56K 0.01% 1301
2019
Q3 		$70K Buy
+6,100
New +$101K 0.01% 1304
2019
Q1 		– Sell
-68
Closed -$1.5K – 4777
2018
Q4 		$1K Hold
68
– – ﹤0.01% 3723
2018
Q3 		$1K Sell
68
-300
-82% -$8.58K ﹤0.01% 3883
2018
Q2 		$10K Buy
368
+300
+441% +$7.99K ﹤0.01% 2688
2018
Q1 		$1K Sell
68
-932
-93% -$22.2K ﹤0.01% 4174
2017
Q4 		$21K Sell
1,000
-400
-29% -$9.14K ﹤0.01% 2529
2017
Q3 		$34K Sell
1,400
-4,690
-77% -$103K ﹤0.01% 2625
2017
Q2 		$118K Sell
6,090
-200
-3% -$3.63K ﹤0.01% 1726
2017
Q1 		$116K Sell
6,290
-5,810
-48% -$114K ﹤0.01% 1598
2016
Q4 		$229K Buy
12,100
+11,900
+5,950% +$243K 0.01% 1201
2016
Q3 		$4K Sell
200
-8,483
-98% -$161K ﹤0.01% 5204
2016
Q2 		$154K Buy
8,683
+214
+3% +$3.46K 0.01% 1324
2016
Q1 		$115K Sell
8,469
-16,569
-66% -$251K 0.01% 1484
2015
Q4 		$482K Buy
+25,038
New +$500K 0.03% 632

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cutler Group's TVTX Position: Q1 2024 in Review

Cutler Group reduced its Travere Therapeutics (TVTX) stake by 30% in Q1 2024, selling an estimated $5.06K and leaving 1,400 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Cutler Group first reported a position in TVTX in Q4 2015 and has held it in 26 quarters since. The position peaked at $482K in Q4 2015. 175 funds tracked by Wall St. Rank hold TVTX as of Q1 2024.

  • Cutler Group held 1,400 shares of Travere Therapeutics worth $10K as of Q1 2024.
  • Cutler Group sold 600 Travere Therapeutics shares in Q1 2024, an estimated $5.06K.
  • Travere Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1290 holding.
  • Cutler Group first reported a position in Travere Therapeutics in Q4 2015 and has held it in 26 quarters since.
  • Cutler Group's Travere Therapeutics position peaked at $482K in Q4 2015.
  • 175 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.